rdf:type |
|
lifeskim:mentions |
umls-concept:C0019004,
umls-concept:C0020503,
umls-concept:C0030705,
umls-concept:C0042117,
umls-concept:C0087111,
umls-concept:C0205191,
umls-concept:C1337242,
umls-concept:C1367459,
umls-concept:C1435704,
umls-concept:C1512518,
umls-concept:C1704419,
umls-concept:C1705819,
umls-concept:C1865871
|
pubmed:issue |
1
|
pubmed:dateCreated |
2007-8-20
|
pubmed:abstractText |
This 1-year double-blind, placebo-controlled, multicenter study evaluated the long-term safety and efficacy of cinacalcet for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0301-0430
|
pubmed:author |
pubmed-author:ArrudaJ AJA,
pubmed-author:BahnerUU,
pubmed-author:BlockG AGA,
pubmed-author:CorpierCC,
pubmed-author:DisneyAA,
pubmed-author:KlassenP SPS,
pubmed-author:OlsonK AKA,
pubmed-author:SchwanauerL ELE,
pubmed-author:SorokaS DSD,
pubmed-author:SterrettJ RJR,
pubmed-author:StrohOO,
pubmed-author:StummvollH KHK
|
pubmed:issnType |
Print
|
pubmed:volume |
68
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
10-7
|
pubmed:meshHeading |
|
pubmed:year |
2007
|
pubmed:articleTitle |
Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.
|
pubmed:affiliation |
St. Joseph Regional Medical Center, Paterson, NJ, USA. reidsterrett@yahoo.com
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|